Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

Related Content:

OncLive TVGenitourinary CancersImmuno-OncologyImmunotherapy in GU Cancers
OncLive’s September Roundup of Key FDA Approvals in Oncology
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer